rs970548
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001282866.2(MARCHF8):c.102+15281T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.234 in 152,122 control chromosomes in the GnomAD database, including 4,386 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.23 ( 4386 hom., cov: 32)
Consequence
MARCHF8
NM_001282866.2 intron
NM_001282866.2 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.526
Publications
64 publications found
Genes affected
MARCHF8 (HGNC:23356): (membrane associated ring-CH-type finger 8) MARCH8 is a member of the MARCH family of membrane-bound E3 ubiquitin ligases (EC 6.3.2.19). MARCH enzymes add ubiquitin (see MIM 191339) to target lysines in substrate proteins, thereby signaling their vesicular transport between membrane compartments. MARCH8 induces the internalization of several membrane glycoproteins (Goto et al., 2003 [PubMed 12582153]; Bartee et al., 2004 [PubMed 14722266]).[supplied by OMIM, Apr 2010]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91).
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.289 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MARCHF8 | NM_001282866.2 | c.102+15281T>G | intron_variant | Intron 2 of 7 | ENST00000453424.7 | NP_001269795.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MARCHF8 | ENST00000453424.7 | c.102+15281T>G | intron_variant | Intron 2 of 7 | 1 | NM_001282866.2 | ENSP00000411848.2 |
Frequencies
GnomAD3 genomes AF: 0.234 AC: 35588AN: 152004Hom.: 4386 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
35588
AN:
152004
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.234 AC: 35587AN: 152122Hom.: 4386 Cov.: 32 AF XY: 0.237 AC XY: 17586AN XY: 74326 show subpopulations
GnomAD4 genome
AF:
AC:
35587
AN:
152122
Hom.:
Cov.:
32
AF XY:
AC XY:
17586
AN XY:
74326
show subpopulations
African (AFR)
AF:
AC:
8158
AN:
41522
American (AMR)
AF:
AC:
4532
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
AC:
596
AN:
3466
East Asian (EAS)
AF:
AC:
299
AN:
5178
South Asian (SAS)
AF:
AC:
1138
AN:
4818
European-Finnish (FIN)
AF:
AC:
2997
AN:
10548
Middle Eastern (MID)
AF:
AC:
73
AN:
294
European-Non Finnish (NFE)
AF:
AC:
17025
AN:
67974
Other (OTH)
AF:
AC:
503
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1401
2801
4202
5602
7003
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
378
756
1134
1512
1890
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.